



EHA2022 abstracts: What's hot in multiple myeloma?

To help navigate the exciting content being presented at the EHA2022 Congress, the Multiple Myeloma Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in multiple myeloma and other plasma cell dyscrasias.



This educational resource is supported through funds from pharmaceutical companies—a full list of our supporters can be found at <https://multiplemyelomahub.com/>. All content is developed independently by SES in collaboration with the faculty. The funders are allowed no influence on the content of this resource.

Newly diagnosed multiple myeloma

LB2366	<u>Phase 3 DETERMINATION trial in newly diagnosed multiple myeloma: lenalidomide, bortezomib and dexamethasone (RVD) ± autologous stem cell transplantation and lenalidomide maintenance to progression</u>
S175	<u>ATLAS: A phase 3 randomized trial of carfilzomib, lenalidomide, and dexamethasone versus lenalidomide alone after stem-cell transplant for multiple myeloma</u>
S176	<u>Daratumumab, carfilzomib, lenalidomide, and dexamethasone as induction therapy in high-risk transplant eligible newly diagnosed myeloma patients: Results of the phase 2 study IFM 2018-04</u>
S178	<u>Safety and efficacy of belantamab mafodotin in combination with Rd in newly diagnosed, transplant ineligible multiple myeloma patients: A phase 1/2 study by the Hellenic Society of Hematology</u>
S179	<u>Randomized comparison between KRd and KTd induction, followed by K maintenance or observation in transplant non-eligible patients with NDMM (AGMT-MM02 trial)</u>

Relapsed/refractory multiple myeloma

S103	<u>Efficacy and safety of ARI0002H, an academic BCMA-directed CAR-T cell therapy with fractionated initial therapy and booster dose in patients with relapsed/refractory multiple myeloma</u>
S184	<u>Evaluating teclistamab in patients with relapsed/ refractory multiple myeloma following exposure to other B-cell maturation antigen (BCMA)-targeted agents</u>
S185	<u>CARTITUDE-2 Cohort B: Updated clinical data and biological correlative analyses of ciltacabtagene autoleucel in patients with multiple myeloma and early relapse after initial therapy</u>
S188	<u>Teclistamab in combination with daratumumab, a novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma: Updated phase 1b results</u>
S263	<u>Phase I open-label single arm study of GPRC5D CAR-T cells (ORICAR-017) In patients with relapsed/refractory multiple myeloma (POLARIS)</u>
P1463	<u>Phase I dose escalation of LAVA-051, a novel bispecific gamma-delta T-cell engager (GAMMABODY™), in relapsed/refractory hematological malignancies</u>

Other

S244	<u>Effect of anti-spike neutralizing monoclonal antibodies on COVID-19 progression and time to viral clearance in patients with hematological malignancies and SARS-COV-2 infection: The GIMEMA experience</u>
P914	<u>Efficacy and safety of belantamab mafodotin monotherapy in patients with relapsed or refractory light chain amyloidosis: A phase 2 study by the European Myeloma Network</u>

MultipleMyelomaHub

Follow us on Twitter to keep up to date
with the latest from the EHA2022
Congress!

@MM_Hub

#EHA2022

multiplemyelomahub.com